KBC Group’s Capricor Therapeutics CAPR Stock Holding History

KBC Group’s Portfolio CAPR Stock Details CAPR Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q3	–	Sell	-1,461	Closed	-$35K	–	1839
2026 Q2	$35K	Hold	1,461	–	–	﹤0.01%	1798
2026 Q1	$44K	Buy	+1,461	New	+$38.9K	﹤0.01%	1689

Other funds holding CAPR

Geode Capital Management Boston, Massachusetts $1.92T AUM 36.1% 1-Year Est. Return

Citigroup New York $308B AUM 40.94% 1-Year Est. Return

Barclays London, United Kingdom $500B AUM 36.84% 1-Year Est. Return

Squarepoint New York $90.8B AUM 26.98% 1-Year Est. Return

HBK Sorce Advisory Erie, Pennsylvania $5.18B AUM 12.38% 1-Year Est. Return

Oppenheimer & Co New York $9.5B AUM 27.65% 1-Year Est. Return

Bank of New York Mellon New York $608B AUM 32.77% 1-Year Est. Return

Black Diamond Financial Towson, Maryland $1.18B AUM 15.24% 1-Year Est. Return

LPL Financial San Diego, California $468B AUM 17.69% 1-Year Est. Return

Commonwealth Equity Services Waltham, Massachusetts $77B AUM 19.24% 1-Year Est. Return

KBC Group's CAPR Position: Q3 2026 in Review

KBC Group sold out of Capricor Therapeutics (CAPR) in Q3 2026, closing a stake of 1,461 shares — an estimated $35K sold.

KBC Group first reported a position in CAPR in Q1 2026 and held it in 2 quarters. The position peaked at $44K in Q1 2026. 52 funds tracked by Wall St. Rank hold CAPR as of Q3 2026.

KBC Group reported no remaining Capricor Therapeutics position as of Q3 2026 after selling out during the quarter.
KBC Group sold 1,461 Capricor Therapeutics shares in Q3 2026, an estimated $35K.
KBC Group first reported a position in Capricor Therapeutics in Q1 2026 and held it in 2 quarters.
KBC Group's Capricor Therapeutics position peaked at $44K in Q1 2026.
52 funds tracked by Wall St. Rank held Capricor Therapeutics as of Q3 2026.

Based on KBC Group's 13F filing for Q3 2026, filed 22 Oct 2026.